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Objective: To identify disease-causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and
provide targeted replacement therapy.
Methods: We performed genome-wide sequencing, homozygosity mapping, and segregation analysis for novel
disease-causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titra-
tion calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was fur-
ther supported by enzymatic assays and mass spectroscopy on recombinant protein, patient-derived fibroblasts,
plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating scales, electrophys-
iology, and biochemical quantification.
Results: We identified biallelic mutations in PDXK in 5 individuals from 2 unrelated families with primary axonal poly-
neuropathy and optic atrophy. The natural history of this disorder suggests that untreated, affected individuals become
wheelchair-bound and blind. We identified conformational rearrangement in the mutant enzyme around the ATP-
binding pocket. Low PDXK ATP binding resulted in decreased erythrocyte PDXK activity and low pyridoxal 50-
phosphate (PLP) concentrations. We rescued the clinical and biochemical profile with PLP supplementation in 1 family,
improvement in power, pain, and fatigue contributing to patients regaining their ability to walk independently during
the first year of PLP normalization.
Interpretation: We show that mutations in PDXK cause autosomal recessive axonal peripheral polyneuropathy lead-
ing to disease via reduced PDXK enzymatic activity and low PLP. We show that the biochemical profile can be res-
cued with PLP supplementation associated with clinical improvement. As B6 is a cofactor in diverse essential
biological pathways, our findings may have direct implications for neuropathies of unknown etiology characterized
by reduced PLP levels.
ANN NEUROL 2019;86:225–240
Peripheral neuropathies are among the most commonneurological disorders worldwide, affecting approxi-
mately 20 million people in Europe and the USA alone,
with few disease-modifying treatments established for
these conditions.1–3 Inherited forms of peripheral neu-
ropathies affecting both the motor and sensory nerves,
known as Charcot–Marie–Tooth disease (CMT), are
the most common genetic neuromuscular disorders,
affecting approximately 1 in 2,500 people.4–8 However,
only 25% of all autosomal recessive (AR) CMT cases
have causal variants identified,9 and treatment is only
supportive.1–3 Most known genes associated with AR
CMT cause disease either by affecting the cytoskeleton
or axonal trafficking.2
Subjects and Methods
Study Participants
Patients with polyneuropathy and optic atrophy were identified
by neurogeneticists at the National Hospital for Neurology and
Neurosurgery London and Children’s Hospital of Eastern
Ontario. The affected cases were recruited along with unaffected
family members under institutional review board/ethics-approved
research protocols (University College London Hospitals:
04/N034; Children’s Hospital of Eastern Ontario: CTO/1577)
with informed consent. All cases had extensive genetic, meta-
bolic, and mitochondrial investigations carried out that excluded
acquired and other inherited causes of polyneuropathy and optic
atrophy.
Phenotype and Clinical Measures
All cases had comprehensive phenotyping performed by neu-
rogenetics specialists including clinical assessment, electro-
physiology, neuroimaging, and videography. Motor function
was quantified using the Medical Research Council (MRC)
muscle scale, a standardized scale for the assessment of the
peripheral nervous system (PNS) that grades muscle power
from 0 to 5 in 6 validated movements and provides a total
score of a possible 60 points. The disease severity and progres-
sion were assessed using the validated Neurological Im-
pairment Scale (NIS)10 and the Charcot-Marie-Tooth
Neuropathy Score version 2 (CMTNS2). CMTNS2 is a reli-
able and valid composite of symptoms (3 items), signs
(4 items), and neurophysiology (2 items). It is designed to
measure length-dependent motor and sensory impairment in
genetic neuropathies.11,12 The NIS forms part of the standard
minimum dataset for the Functional Independence Measure
and UK Functional Assessment Measure. It records the sever-
ity of functional impairment (rated 0–3) across 13 domains
mapped onto the International Classification of Functioning.
The score range is 0 to 50. The affected individuals from
Family 1 had MRC scales, CMTNS2, and NIS assessment
before and after replacement therapy.
Genome-wide Sequencing and Haplotype
Analysis
DNA was extracted from peripheral blood. Whole genome
sequencing (WGS) was performed by deCODE genetics
(Reykjavík, Iceland), using DNA from the 2 affected siblings
from Family 1. A HiSeq4000 instrument (Illumina, San Diego,
CA) was used to generate 100bp paired-end reads. Alignment
was performed using BWA (http://bio-bwa.sourceforge.net/)13
with GRCH37 as a reference. Variants were called using the
GATK14–17 Unified Genotyper-based pipeline14–16 workflow.
All variants were annotated using ANNOVAR18 and filtered
using custom R scripts. Shared regions of homozygosity were
identified using HomozygosityMapper19 and Bcftools/RoH.20
Only novel or very rare variants with a minor allele frequency of
<0.01 in the 1000 Genomes Project,21 NHLBI GO Exome
Sequencing,22 and Exome Aggregation Consortium database23
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were included. Coding/splicing homozygous variants that were
within the autozygome of the affected cases were prioritized.
Whole exome sequencing (WES) was performed in Family
2 using DNA from both affected siblings and their unaffected
mother as part of the Care4Rare Canada Consortium. Exonic
DNA was selected using the SureSelect Clinical Research Exome
V1 kit (Agilent Technologies, Santa Clara, CA), then sequenced on
an Illumina NextSeq 500 with 2 × 150bp chemistry. Read align-
ment, variant calling, and annotation were done as outlined for pre-
vious FORGE and Care4Rare Canada projects.24 Average coverage
for the exomes was 182×, 190×, and 244×, and >97% of consen-
sus coding sequence exons in all exomes were covered at >10×.
Sanger Sequencing
The variants identified by WGS andWES were confirmed by Sanger
sequencing. The region was amplified using the following primers:
50-AGGAGGATCAGGGATGGGAG-30 and 50-CTCTCATAT
CCTGCTCCCCA-30 in Family 1 and 50-CTTGCCGCTCTAT
GTTTGGAC-30 and 50-GAGAGTGACAGGCGCAACTC-30 in
Family 2. The promoter region of PDXK was amplified using the fol-
lowing primers: 50-GCGGTTCCCTTGGGTATC-30 and 50-ACG
CCTCCTTCTGACCTC-30. Genomic DNA was extracted from
dried blood spots (DBSs) from affected individuals from Family
1 and controls using the QIAamp DNA Micro Kit (Qiagen, Valen-
cia, CA) and from blood from Family 2. Sequencing reactions were
performed using the BigDye Terminator 1.1 system (Thermo Fisher
Scientific, Paisley, UK) followed by sequencing using an ABI DNA
Analyser (Thermo Fisher Scientific). Electropherograms were ana-
lyzed using the Sequencher software package (Gene Codes Corpora-
tion, Ann Arbor, MI).
Gene Co-expression Analysis
We generated gene co-expression networks for central nervous
system (CNS) and PNS tissue-specific transcriptomic data gener-
ated by the Genotype-Tissue Expression Consortium (GTEx7
V6 gene expression data are accessible from https://www.
gtexportal.org/).25 We analyzed each of the tissue sample sets
separately by filtering genes on the basis of an Reads Per Kilobase
Million (RPKM) >0.1 (observed in >80% of the samples for a
given tissue). We then corrected for batch effects, age, gender,
and RNA integrity numbers (RIN) using ComBat.26 Finally, we
used the residuals of these linear regression models to construct
gene co-expression networks for each tissue using WGCNA27
and postprocessing with k-means28 to improve gene clustering.
Gene modules were functionally annotated with gProfileR4 R
package using the Gene Ontology (GO) database without elec-
tronic inferred annotations and accounting for multiple testing
with gSCS.29 The top-down plot figure was done with Cyto-
scape 3.5.1.30 We initially selected the 50 most connected genes
within the black module, for the coexpression network of tibial
nerve, based on adjacency values. We included all connections
between genes. Then we filtered out the connections with
weight <0.05. Finally, we applied a Kamada–Kawai layout algo-
rithm to the remaining genes and edges to dispose them spatially
at the canvas so their relative positions reflected similarity in
connections.
Plasmid Constructs
The human PDXK wild-type (WT) and PDXK mutant
p.Ala228Thr cDNA were purchased from Invitrogen (Carlsbad,
CA) and cloned into the plasmid pGEX6p-1 (GE Healthcare,
Piscataway, NJ) using the sites BamHI and NotI (New England
Biolabs, Ipswich, MA).
Protein Purification
Escherichia coli strain Rosetta2 (DE3; Novagen, Darmstadt,
Germany) was transformed with the plasmids pGEX6p-1-PDXK
and pGEX6p-1-PDXK p.Ala228Thr and grown at 37C to an
OD600nm of 0.8 and then induced with 0.5mM isopropyl β-D-
1-thiogalactopyranoside for 4 hours. Cells were lysed, using a cell
disruptor (Avestin, Ottawa, Ontario, Canada), in lysis buffer
containing 25mM hydroxyethylpiperazine ethane sulfonic acid
(HEPES), pH 7.4, 400mM KCl, 4% Triton X-100, 1mM 1,4-
dithiothreitol (Sigma-Aldrich, Gillingham, UK), and SIGMAFAST
Protease Inhibitor Cocktail Tablets, EDTA-Free (Sigma-Aldrich).
The samples were supplemented with 5% polyethylamine (Sigma-
Aldrich) and clarified using a 45Ti rotor (Beckman Coulter, Brea,
CA) at 100,000 × g for 30 minutes prior to incubation overnight
at 4C with glutathione agarose beads (Pierce, Rockford, IL) previ-
ously washed in lysis buffer containing 1% Triton X-100. The
glutathione agarose beads containing the immobilized proteins
GST-PDXK and PDXK p.Ala228Thr were subsequently washed
in lysis buffer containing 1% Triton X-100 and incubated with
10mg/ml DNAse and RNAse (Sigma-Aldrich) for 1 hour at room
temperature (RT), prior to washing in lysis buffer containing no
Triton X-100. The GST tag was cleaved using 100U of PreScission
Protease (GE Healthcare) for 2 hours at RT. After elution, the
proteins were dialyzed in 25mM HEPES, pH 7.4, 100mM KCl,
1mM 1,4-dithiothreitol overnight at 4C. Protein concentration
was determined using the BCA Protein Assay Kit (Thermo Fisher
Scientific).
Circular Dichroism
To investigate conformational differences between WT PDXK
and the disease-linked mutant p.Ala228Thr, circular dichroism
(CD) analyses were performed. The extinction coefficients of
both proteins (ε280 = 31,400M−1cm−1) were calculated using
the ProtParam tool within the ExPASy Portal.31 Proteins were
prepared as described above and dialyzed overnight at 4C in
30mM tris, pH 7, 100mM KCl, 3mM MgCl2, 0.5mM tris
(2-carboxyethyl)phosphine (TCEP). Samples were concentrated
to 0.2mg/ml using Amicon Ultra 0.5ml centrifugal filters
(Merck, Darmstadt, Germany).
Ultraviolet (UV) and CD spectra were acquired on the
Applied Photophysics (Leatherhead, UK) Chirascan Plus spec-
trometer across the 400 to 190nm wavelength region. Ten-
millimeter (400–230nm) and 0.5mm (260–190nm) strain-free
rectangular cells were employed. The instrument was flushed
continuously with pure evaporated nitrogen throughout the
experiment. The following parameters were employed: 2nm
spectral bandwidth, 1nm step size, and 1-second instrument
measurement time-per-point. All spectra were acquired at 25C,
and buffer baseline corrected. Light scattering correction was
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applied on the UV spectra of both proteins using the Chirascan
Pro-Data Software (Applied Photophysics). Where possible, spec-
tra were smoothed with a window factor of 4 using the
Savitzky–Golay method32 for better presentation.
The far-UV CD spectra of the 2 proteins were corrected
for concentration and pathlength and expressed in terms of Δε
(M−1cm−1) per amino acid residue. Protein secondary structure
content was assessed using the Principle Component Regression
method based on 16 known protein structures31 embedded in
the PLSPlus/IQ routine in GRAMS32 AI software (Galactic
Software, Salem, MA).
Isothermal Titration Calorimetry
The affinity of a nonhydrolyzable analogue of adenosine triphos-
phate (ATP), called adenosine 50-(3-thiotriphosphate) tetralithium
salt (ATPγS), for both PDXK WT and p.Ala228Thr mutant, was
examined using a MicroCal Isothermal Titration Calorimeter
ITC200 instrument (Malvern Panalytical, Malvern, UK). Both
proteins were prepared as described above in 30mM tris, pH
7, 100mM KCl, 3mM MgCl2, 0.5mM TCEP (isothermal titra-
tion calorimetry [ITC] buffer). An initial 0.2M stock of ATPγS
was prepared in water and diluted with ITC buffer to a final con-
centration of 250μM. The concentration was adjusted using the
UV absorbance at 259nm, and the extinction coefficient of
15.4mM−1cm−1 suggested by the ligand provider (Jena Biosci-
ence, Jena, Germany).
The experiments were conducted at 25C following stan-
dard procedures as described previously.33 Forty microliters of
250μM ATPγS was titrated into a 330μl solution of 25μM WT
or p.Ala228Thr protein. The ITC experiment consisted of
twenty 2μl injections with a spacing of 180 seconds. Heat pro-
duced by titrant dilution was obtained by a control experiment,
titrating into buffer alone, under the same conditions.
The MicroCal-Origin 7.0 software package was used to fit
the integrated heat data obtained for the titrations corrected for
heats of dilution, using a nonlinear least-squares minimization
algorithm based on an independent binding sites model. ΔH
(reaction enthalpy change in kcal/mol), Ka (1/KD; equilibrium
association constant per molar), and n (molar ratio of the pro-
teins in the complex) were the fitting parameters. The reaction
entropy was calculated using the relationships ΔG = ΔH −
TΔS = −RTln(1/KD).
Western Blotting
Fibroblast samples from affected, carriers, and healthy people
were obtained with consent. After reaching 90% confluence, the
cultured cells were harvested and lysed in ice-cold lysis
radioimmunoprecipitation assay buffer containing 50mM tris-
HCl pH 8.0, 150mM NaCl, 0.5% DOC, 0.1% Triton X-100,
0.1% sodium dodecyl sulphate (SDS), and SIGMAFAST
Protease Inhibitor Cocktail for 30 minutes. The lysate was
then centrifuged at 16,000 × g at 4C, and the supernatant
transferred to a new tube. The protein concentration was mea-
sured using the BCA Protein Assay Kit (Thermo Fisher Scien-
tific) according to manufacturer’s protocol. Equal amounts of
protein (30μg) from affected and healthy individuals were
separated on a 10% SDS–polyacrylamide gel electrophoresis gel
(NuPAGE, Invitrogen) and transferred onto an Immobilon
membrane (Millipore, Billerica, MA). After blocking the mem-
brane with 2% fat-free milk in phosphate-buffered saline–Tween
for 1 hour at RT, the membrane was incubated with anti-PDXK
antibody (Abcam, Cambridge, UK; 38208, 1:500) for 1 hour at
RT. The membranes were subsequently washed and incubated
with horseradish peroxidase–conjugated goat antirabbit IgG
(Bio-Rad Laboratories, Hercules, CA; 17210, 1:5,000) for 1 hour
at RT. Blots were developed using ECL Prime (GE Healthcare),
visualized via a ChemiDoc Touch Imaging System (Bio-Rad
Laboratories), and analyzed using Image Lab 5.2 software (Bio-
Rad Laboratories). For the quantification, the signal intensity
of each band corresponding to the PDXK WT and PDXK
p.Ala228Thr mutant protein was normalized to the signal inten-
sity of the corresponding reversible Ponceau staining as a reliable
loading control.34 The amount of PDXK WT and mutant pro-
tein was expressed as a percentage of the control sample. The
experiment was repeated 3 times.
Measurement of Pyridoxal Kinase Activity
The pyridoxal (PL) kinase activity present in DBSs was deter-
mined by adapting the protocol used by Wilson et al,35 with the
following modifications. Three-millimeter discs punched from
DBSs were incubated for 10 minutes at 37C with shaking at
300rpm in a reaction buffer containing 20mmol/l potassium
phosphate adjusted to pH 6.1, 10μmol/l PL, and 300μmol/l
MgATP (all purchased from Sigma-Aldrich). The same method
was adapted for the investigation of activity of the purified
recombinant PL kinase. Five microliters of 20ng/μl purified PL
kinase protein lysate was placed in an ultraperformance liquid
chromatography (UPLC) 96-well sample plate (Waters, Elstree,
UK). Subsequently, 115μl of reaction buffer containing potas-
sium phosphate (pH 6.1), PL, and MgATP was added to create
a final concentration of 20mmol/l potassium phosphate, with PL
and MgATP concentrations adjusted as appropriate. Investiga-
tion of PL kinase kinetics as a function of PL concentration used
an MgATP concentration of 300μmol/l. A PL concentration of
50μmol/l was utilized for the determination of PL kinase kinetics
as a function of MgATP concentration. After reaction buffer
addition, the plate was incubated for 10 minutes at 37C in an
Eppendorf (Hamburg, Germany) Thermomixer C with shaking
at 300rpm prior to addition of 120μl of a reaction stop mix
identical to that used for the determination of pyridoxamine
(PM) 50-phosphate (PMP) oxidase activity from DBSs.
DBSs were collected from 4 affected cases and 22 controls
(age = 15–92 years). PL kinase activity of the recombinant pro-
teins and that of DBSs were determined by using UPLC–tandem
mass spectrometry (MS/MS) to determine the formation of PL
50-phosphate (PLP) after incubation of these with the enzyme
substrate PL and expressed as μmol PLP l−1h−1 from recombi-
nant protein and as pmol PLP (3mm DBS)−1h−1 from DBSs.
Data collection and statistical analysis were performed
using Waters MassLynx and GraphPad (San Diego, CA) Prism
6.0 software packages.
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UPLC-MS/MS Measurement of the B6 Vitamers
B6 vitamer concentrations (pyridoxine, PL, PLP, PM, PMP) and
pyridoxic acid were quantified by UPLC-MS/MS using stable
isotope-labeled internal standards.35,36
High-Performance Liquid Chromatograph
Measurement of B6 Vitamers
PL phosphate was measured by high-performance liquid chromatog-
raphy (HPLC) with fluorescence detection using a Chromsystems
Instruments & Chemicals (Gräfelfing, Germany) kit as described
previously.35 Pyridoxic acid concentration was calculated using an
external calibration standard.
PLP Measurements before and after PLP
Replacement
Plasma PLP concentrations before and after PLP replacement
were measured using 2 independent HPLC and UPLC-MS/MS
methods as described above to validate the results.
The difference between groups was tested with the use of a
1-way analysis of variance test, followed by Tukey–Kramer test.
Measurement of Neurofilament Light Chain
Concentration
Plasma neurofilament light chain (NFL) concentration was mea-
sured by digital enzyme-linked immunosorbent assay using the
commercially available NF-Light kit on a single molecule array
(Simoa) platform (HD-1 Analyzer) according to instructions by
the manufacturer (Quanterix, Lexington, MA). All measure-
ments were performed in duplicates, in 1 round of experiments
using 1 batch of reagents. Intra-assay coefficients of variation
were <10%.
Results
Here, we describe 5 affected cases from 2 unrelated fami-
lies (Fig 1A) with early, childhood onset, sensorimotor,
length-dependent, predominantly axonal polyneuropathy
and adult onset optic atrophy (Table 1).
Disease Characterization
Family 1 is of Cypriot origin (affected individuals F1-II-5,
currently 80 years old, F1-II-6, currently 75 years old, and
F1-II-9, died at 71 years old from an unrelated medical
condition). Three affected siblings presented with difficul-
ties running, distal wasting, and weakness in the lower
limbs before the age of 10 years, progression to upper limbs
by the age of 12 years, and onset of visual loss in their 40s.
The disease progressed, and at the age of 79 years, case
F1-II-5 required the assistance of 2 people for sit-to-stand,
mobilizing with the assistance of 2 plus Zimmer frames for
transfers and short distances, and using a wheelchair for all
other activities. Neurogenic-type pain, particularly in the
lower limbs, was difficult to control despite multiple lines
of symptomatic treatment. Case F1-II-6 (age = 74 years)
could only walk short distances with assistance from
1 individual. Neurological examination showed bilateral
distal wasting from mid forearm and below the knee, with
wasting of the thenar, hypothenar, and intrinsic muscle of
the hands and distal lower limb muscles, pes cavus, and
absent reflexes throughout in both patients (see Fig 1B).
The MRC muscle score was 44 (of 60) in cases F1-II-5
and F1-II-6. Strikingly, both patients had severely reduced
sensation in all limbs and in all modalities, with profound
joint position sense loss up to the knee and vibration loss
up to the iliac crest in both cases (see Table 1 and Supple-
mentary Table 1). Vision was reduced (including color
vision) and fundoscopy confirmed bilateral optic atrophy
in both cases (see Fig 1C). The remaining cranial nerve
examination was normal. The third sibling F1-II-9 (now
deceased) was similarly affected.
Family 2 is of Scottish (paternal) and Italian (maternal)
origin with 2 affected sisters (Patient F2-II-1, currently
31 years old; Patient F2-II-2, currently 29 years old) who
presented with childhood onset of a mild decrease in balance,
which progressed to difficulty with running in adolescence,
and then to mild distal hand weakness in the 3rd decade.
Both sisters ambulate independently without aids, and nei-
ther sister has symptoms of visual loss at their present ages.
Neurological examination showed mild symmetrical distal
wasting in hand intrinsic muscles and prominent distal lower
limb muscle wasting with pes cavus and mild hammertoes.
There was mild distal weakness in hand intrinsic muscles, in
the upper limbs, and in the toes and distal lower legs and
feet. The MRC scores were 56 (F2-II-1) and 54 (F2-II-2).
Both sisters were areflexic, with reduced pinprick sense in the
lower extremities and decreased vibration sense to the knees
(see Table 1 and Supplementary Table 1). Color vision was
reduced. Fundoscopy confirmed bilateral optic atrophy in
both cases; the remainder of the cranial nerve examination
was normal.
Nerve conduction studies (NCS) in all affected cases
revealed a progressive, length-dependent, sensorimotor, pre-
dominantly axonal neuropathy (Supplementary Table 2).
Early in the disease (as seen in Family 2), the NCS show a
predominantly axonal neuropathy affecting mainly the
lower limbs with absent sensory responses. Mild conduc-
tion slowing with normal motor responses was recorded in
the upper limbs. The natural history of this disorder in the
older individuals from Family 1 (F1-II-5 and F1-II-6) with
data recorded over 20 years of disease duration suggests that
untreated, the neuropathy progresses in a length-dependent
fashion and is characterized by prolonged distal motor
latency (DML), severe reduction of compound muscle
action potentials (CMAPs), and absent sensory responses
affecting upper and lower limbs, as confirmed on NCS.
Interestingly, both patients present with significantly more
prolonged DML in the median compared to ulnar nerve
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(6.1 vs 3.6 milliseconds). Although it is possible that this is
secondary to a longstanding median compression lesion at
the wrist, we cannot exclude that this finding is disease-
related. The reduced CMAPs were associated with reduc-
tion of conduction velocities in the intermediate range
mainly in the median nerves. Electromyography in all cases
tested was consistent with chronic denervation with no
myopathic changes.
To further ascertain the exact type of neuropathy,
we performed a nerve biopsy in case F1-II-6. It showed
diffuse and severe depletion of both small and large mye-
linated axons with regenerating clusters but no “onion
FIGURE 1: Biallelic PDXK mutations are associated with axonal polyneuropathy and optic atrophy. (A) Pedigree of the 2 families
with PDXK mutations. * = individuals examined. Arrow = proband. (B) Phenotype of the cases with PDXK mutations presenting
with muscle atrophy of the intrinsic muscles of the hands, with clawing of the hands, thin wrists, pes cavus, and muscle atrophy
in the feet and calves (B1-B3, Case F1-II-5; B4-B6, Case F1-II-6). (C) Fundoscopy-confirmed bilateral optic disc atrophy in both
cases (C1, F1-II-5; C2, F1-II-6). (D) Nerve biopsy from Case F1-II-6 showing axonopathy. There is diffuse and severe depletion of
both small and large myelinated axons with most of the surviving axons being <5μm in diameter. There were no axonal ovoids,
but there were regenerating clusters (arrows) consistent with longstanding indolent axonopathy. There was no demyelination
process. (E) Sanger sequencing confirming the homozygous c.682G>A mutation in the 2 affected siblings and heterozygous
state in an unaffected family member in Family 1, and homozygous c.659G>A in the 2 affected siblings and segregation in
Family 2. (F) Vitamin B6 metabolic pathway. Phosphorylated B6 vitamers (pyridoxamine 50-phosphate [PMP]; pyridoxine 50-
phosphate [PNP]; pyridoxal 50-phosphate [PLP]) present in the diet are hydrolyzed to pyridoxal (PL), pyridoxamine (PM), and
pyridoxine (PN) by intestinal phosphatases prior to absorption and then converted to their 50-phosphate derivatives in the liver
by PL kinase (PDXK). PNP and PMP are then converted to PLP by pyridox(am)ine 50-phosphate oxidase (PNPO). PLP re-enters the
circulation bound to a lysine residue of albumin. Homeostatic regulation of tissue levels of PLP is achieved by various
mechanisms, including feedback inhibition of PNPO and PL kinase by PLP.62 Albumin in plasma, hemoglobin in erythrocytes, and
glycogen phosphorylase in muscle also play a role, binding to PLP and helping to keep concentrations of this very reactive
aldehyde low63 so as to avoid any unwanted reactions with biologically important molecules. Subsequent delivery of PLP to the
tissues requires hydrolysis of circulating PLP to PL by the ectoenzyme tissue nonspecific alkaline phosphatase (TNSALP). The
resulting pyridoxal is able to enter cells prior to being rephosphorylated by PL kinase to produce the active cofactor, PLP,
required by B6-dependent apoenzymes.
64 Within cells, recycling pathways also exist, with PMP being oxidized by PNPO to form
PLP.63 AOX = aldehyde oxidase; GPI = glycosylphosphatidylinositol; PA = pyridoxic acid.
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TABLE 1. Detailed Phenotype of the Affected Cases Carrying PDXK Mutations
Phenotype/Case F1-II-5 F1-II-6 F1-II-8 F2-II-1 F2-II-2
Demographics
Gender M F F F F
Age at examination, yr 79 74 Died at 71 years from
leukemia
31 29
Age at onset, yr 7 9 7 5 2
Progression
Symptoms at onset Lower limb weakness and wasting
Upper limb weakness At 12 years At 12 years At 17 years 20s 20s
Optic atrophy At 40 years At 47 years At 50 years 31 29
Neurological examination
Fundoscopy Pale optic discs bilaterally Pale optic discs bilaterally NA Mild optic disc pallor
bilaterally
Mild optic disc pallor
bilaterally
Other cranial nerves Normal
Skeletal deformities Pes cavus, hammer toes,
clawing of hands
Pes cavus,
hammer toes
Power Severe weakness of dorsiflexion/plantar flexion, long finger extensors and intrinsic muscles
of the hands
Moderate–severe weakness of dorsiflexion/plantar flexion,
long finger extensors and mild weakness of intrinsic muscles
of the hands
MRC power score 44 44 56 54
Reflexes Absent throughout; mute
plantar responses
NA Areflexia; mute plantar
responses
Areflexia; mute plantar
responses
Sensation Reduced pain to midcalf and
wrists
Reduced pain to ankles and
elbows
Reduced pain to ankles Reduced pain to upper calf
and base of fingers
Reduced vibration
sense to iliac crest and wrist
Reduced vibration sense
to iliac crest and elbow
Vibration decreased to the
knees
Vibration decreased
to the knees
Romberg sign Present Present Present Present
Coordination Normal Normal Normal Normal
Visual acuities Unable to count fingers 6/12 in both eyes NA NA
Color vision Unable to distinguish any
color
Grossly impaired, 3/17
Ishihara plates
15/17 Ishihara plates 3/17 Ishihara plates
Peripheral vision Normal Normal Normal Normal
Cognitive function Normal Normal Normal Normal
Seizures Absent Absent Absent Absent
Investigation results
MRI head Normal Normal NA NA
Optic nerve and
chiasm CT
Normal Normal NA NA
VEPs Severely attenuated bilaterally with
anomalous waveform on flash VEPs
NA NA
Somatosensory evoked
potentials
NA Poorly formed due to severe
polyneuropathy
NA NA
Nerve conduction
study
Severe sensorimotor axonal
neuropathy
Severe sensorimotor axonal
neuropathy
Severe sensorimotor axonal
neuropathy
Severe sensorimotor axonal
neuropathy
Electromyography Chronic denervation in a length-dependent pattern; no
myopathic changes
Chronic denervation in a length-dependent pattern; no
myopathic changes
Renal function Normal Normal Normal Normal
Biochemical profile
Liver function Normal Normal Normal Normal
GI tract Normal colonoscopy Normal Normal Normal
Plasma amino acids Normal NA NA NA
Vitamin B1, normal
range = 67–265nmol/l
NA 176 149 183
Vitamin B9, normal
range = 3.9–20ng/ml
Normal NA Normal Normal
Vitamin B12, normal
range = 197–771pg/ml
938 454 293 211
Plasma amino acids tested: methionine, isoleucine, leucine, tyrosine, phenylalanine, ornithine, lysine, histidine, and arginine.
CT = computed tomography; F = female; GI = gastrointestinal; M = male; MRC = Medical Research Council; MRI = magnetic resonance imaging;
NA = not available; VEP = visual evoked potential.
bulbs.” This confirms a longstanding axonopathy with no
overt demyelination (see Fig 1D).
All cases reported here had pale optic discs on clini-
cal examination. We performed visual evoked potentials
(VEPs) to further describe the involvement of the optic
nerve in the course of disease. We found that VEPs in
Case F1-II-6 had decreased considerably in amplitude
from 7.9 and 7.4 in each eye to 1.8 and 1.9 over a
20-year period, indicating axonal loss and bilateral visual
pathway involvement (see Supplementary Table 2). Simi-
lar results were confirmed in case F1-II-5. Family 2 has
not been investigated with VEPs.
Identification of Disease-Causing PDXK Variants
Previous extensive genetic,37 metabolic, and mitochondrial
investigations failed to identify any acquired or known
causes of inherited polyneuropathy in all cases. WGS and
homozygosity mapping in Family 1 revealed a shared
homozygous region from 42 to 45Mb on chromosome
21. This region included a shared homozygous variant in
the 2 affected siblings that was carried by unaffected family
members in heterozygous state: PDXK (NM_003681)
c.682G>A (p.Ala228Thr). This variant was absent in
150 Cypriot controls. The p.Ala228Thr is absent from the-
gnomAD database in homozygous state though reported in
7 heterozygous of atotal of 250586 alleles (total allele fre-
quency of 0.00002793).23
Independently, homozygosity mapping in Family
2 revealed a 1.35Mb region of homozygosity on chromo-
some 21. WES in Family 2 identified a shared homozygous
variant in this region, the c.659G>A p.(Arg220Gln) in the
2 affected sisters, carried by each parent. This variant is
absent from gnomAD in homozygous state and reported in
5 heterozygous European alleles from 250146 (total allele
frequency of 0.00001999).23 It is predicted to be deleteri-
ous to protein function by in silico programs (Combined
Annotation Dependent Depletion score = 24). Sanger
sequencing in affected individuals and carriers confirmed
both variants (see Fig 1E).
PDXK is ubiquitously expressed in humans encoding
for PL kinase (PDXK), a cytoplasmic protein that converts
vitamin B6 to its active form, PLP (see Fig 1F). PLP is an
essential cofactor for >70 human enzymes representing
diverse, essential biological pathways including amino acid
and neurotransmitter metabolism.
Because PDXK mutations produce a peripheral
rather than a predominantly CNS disease, we investigated
these differences further in silico using public bulk tissue25
and cell-specific transcriptomic data.38 This demonstrated
that human peripheral (tibial–mixed motor and sensory)
nerve is among the tissues with the highest expression of
PDXK (Fig 2A), with evidence for expression specifically
in peripheral sensory neurons, based on single cell mouse
transcriptomic data (see Fig 2B).38 This showed different
co-expression profiles in brain compared to peripheral
nerve tissue. Weighted gene co-expression analysis demon-
strated that in 9 of 11 brain regions analyzed, PDXK was
coexpressed with genes relating to synaptic transmission
and neuronal identity, whereas co-expression data from
the tibial nerve showed that PDXK was located within a
module enriched for genes involved in oxidation-reduction
processes (GO: 055114; false discovery rate–corrected
p = 2.36 × 10−9; see Fig 2C and Supplementary Table 3).
Assessment of the Impact of PDXK Variants on
Protein Structure and Enzymatic Activity
Arginine 220 and alanine 228 are evolutionarily conserved
amino acids in eutherians (see Fig 2D). Arginine 220 is
located in the β9 in the vicinity of the ATP-binding site.39
Alanine 228 is located in the ATP-binding pocket of PL
kinase (see Fig 2E), a critical region of the kinase, part of
the loop region between strand β11 and helix α7 that
rotates away from the active site, allowing binding of the
ATP adenine.39 Although the Ala228 side-chain does not
contact ATP directly, its backbone is involved in rec-
ruiting ATP to the catalytic pocket.
Far-UV CD spectra analysis of both WT and
p.Ala228Thr revealed that, whereas both proteins were
folded, there were small but significant differences in their
secondary structure (Fig 3A). WT PDXK had an estimated
α-helix and β-strand content of 31.2% and 19%, respec-
tively, similar to previous X-ray studies (PDB accession
number 3KEU).40 In the mutant protein, 26.0% and
21.1% of helical and strand content, respectively, were esti-
mated, suggesting altered protein conformation. Further-
more, near-UV CD analysis revealed distinctive CD
fingerprints for WT and p.Ala228Thr proteins, indicating
conformational rearrangements of aromatic side-chains41
around the catalytic pocket, most likely hindering the
enzyme’s ability to bind ATP.
We performed ITC confirming that p.Ala228Thr
affected the ATP-binding ability of PDXK. Interaction of
WT PDXK with the nonhydrolyzable ATP analogue ATPγS
generated well-interpolated, sigmoid-shaped curves, based on
an independent and equivalent binding site model centered
on 1:1 stoichiometry. By contrast, no association between p.
Ala228Thr and ATPγS was observed (see Fig 3B).
Whereas no reduction in the expression of the
mutant protein (p.Ala228Thr) compared to WT PDXK
in case-derived fibroblasts was evident (see Fig 3C),
kinetic studies with human recombinant PDXK showed
an approximate 2-fold increase in the Km of the
p.Ala228Thr mutant protein (31.9μmol/l) for PL com-
pared to WT protein (14.5μmol/l) and a reduction in the
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Vmax of the mutant protein (p.Ala228Thr) to
0.95μmol/l/h compared to 2.52μmol/l/h for WT PDXK.
Upon variation of MgATP concentration, sigmoidal
kinetics were observed (WT: k0.5 = 53.4μmol/l,
Vmax = 16.8pmol/h; p.Ala228Thr: k0.5 = 174.4μmol/l,
Vmax = 6.3pmol/h), indicating cooperative binding
between the 2 substrates, ATP and PL (see Fig 3D, E).
Analysis of erythrocyte PDKX activity from cases car-
rying the p.Arg220Gln and p.Ala228Thr substitutions fur-
ther confirmed the deleterious effect of these variants on
PL kinase activity (see Fig 3F). The PDKX activity in the
4 affected cases was reduced (1.1 and 0.8pmol DBS−1h−1
in Family 1 and 1.19 and 0.5pmol DBS−1h−1 in Family 2)
relative to controls (2.6–14.7pmol DBS−1h−1, mean = 8.0).
FIGURE 2: PDXK is highly expressed in the peripheral and central nervous systems and in the same regulon with genes already
linked to axonal peripheral neuropathies. (A) Expression of PDXK in human tissues. Box and whisker plots show the expression of
PDXK across multiple human tissues. Data were generated by the GTEx Consortium. Expression in tibial nerve is highlighted with a
dark gray arrow and is among the tissues with the highest PDXK expression. TPM = Transcripts Per Kilobase Million. (B) Expression
of PDXK in multiple cell types of the mouse central nervous system (CNS) and peripheral nervous system (PNS) generated using
single cell RNA-seq. PDXK gene expression across single cells isolated from the mouse central and peripheral nervous systems and
displayed using a heatmap demonstrates highest expression of this gene in neurons of the mouse hindbrain,38 with expression in
the peripheral neurons including sensory neurons. CB = cerebellum; GC = glial cells; HC = hippocampus; MSN = medium spiny
neurons; NBL = neuroblasts; OB = olphactory bulb; Symp = sympathetic. (C) Top-down plot of the black module genes in the tibial
nerve tissue. Only the most connected genes are shown. PDXK gene is highlighted in yellow. Genes known to be associated with
the Gene Ontology term GO:0055114, oxidation–reduction process, are highlighted in red. The size of gene nodes reflects their
connectivity with the rest of the genes in the module. PDXK is among the top 60 most connected genes. Proximity of genes in the
plot reflects their similarity in terms of shared connections with other genes. Interestingly, within the PDXK regulon from the tibial
nerve, we found DHTKD1 already linked to Mendelian disorders and associated with primary peripheral axonal neuropathy.59,60
(D) Conservation of p. Ala228Thr and p.Arg220Gln in PDXK across species. (E) Crystal structure of human pyridoxal kinase with
bound adenosine triphosphate (ATP; PDB accession number 3KEU). PDXK is a dimeric enzyme with 1 active site per monomer65
(monomers A and B are depicted in green and yellow, respectively). In the PDXK structure, the backbone-carbonyl oxygen of
alanine 228 establishes a hydrogen bond with the adenine NH2 group of ATP. The active site of each monomer binds 1 ATP
molecule, two Mg2+ ions, and 1 Na2+ ion. The ATP-binding site is composed of a β-loop-β structure, often referred as a flap, which
provides numerous hydrogen-bond interactions to the ATP β- and γ-phosphates, and sequesters the ATP for catalysis.39 Arginine
220 is located in the β9, in the vicinity of the ATP-binding site. PDB = Protein Data Bank.
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FIGURE 3: PDXK mutations lead to reduced pyridoxal (PL) kinase enzymatic activity and low PL 50-phosphate (PLP). (A) Circular
dichroism analyses of recombinant PDXK wild-type (WT) and p.Ala228Thr mutant proteins. The left and right panels show the
normalized far-ultraviolet (UV) and near-UV spectra of the 2 proteins, respectively. A clear difference in secondary structure
content between the 2 proteins is observed from the far-UV experiment. CD = circular dichroism. (B) Analysis of the interaction
of nonhydrolyzable analogue adenosine 50-(3-thiotriphosphate) tetralithium salt (ATPγS) with PDXK WT and p.Ala228Thr mutant
proteins by isothermal titration calorimetry. The left panel shows the titration of ATPγS (250μM) into a PDXK WT solution
(25μM). The thermogram shows that the interaction was entropically and enthalpically favored, with ΔH = −3.27  0.42kcal/mol,
TΔS = −4.42  0.48kcal/mol, KD = 2.33  0.25μM, and ΔG = −7.69  0.06kcal/mol. The stoichiometry was 0.80  0.02μM,
indicating that each molecule of PDXK binds to 1 molecule of ATPγS. The right panel reports the titration of ATPγS (250μM) into
a PDXK p.Ala228Thr solution (25μM). The experiment showed no interaction under the experimental conditions tested,
suggesting that the mutation affected the ability of the kinase to bind the analogue substrate ATPγS. (C) Western blot analysis
shows normal expression of the PDXK protein in cases compared to controls. (D) Activity of recombinant WT and p.Ala228Thr PL
kinase protein measured as PLP formation. Conditions: 0–100μmol/l PL, 300μmol/l MgATP, 20mmol/l potassium phosphate,
pH 7.0, 37C, 10-minute incubation with 100ng recombinant protein. Points displayed are a mean of 3 repeats. Vmax:
WT = 2.17μmol/l/h, p.Ala228Thr = 2.52μmol/l/h. Km: WT = 14.53μmol/l, p.Ala228Thr = 31.93μmol/l. MUT = mutant. (E) Kinetics
of recombinant WT and p.Ala228Thr PL kinase protein upon variation of PL concentration. PL kinase activity of recombinant
human WT and p.Ala228Thr PDXK protein is measured as PLP formed after incubation with the substrate PL. Incubations were
performed in the presence of variable concentrations of MgATP (0–500μmol/l) and 50μmol/l PL. Kinetics were sigmoidal, and
parameters established were as follows. WT: k0.5 = 53.4μmol/l, Vmax = 16.8pmol/h; p.Ala228Thr: k0.5 = 174.4μmol/l,
Vmax = 6.3pmol/h. Results indicate a dramatic reduction in the catalytic efficiency of the p.Ala228Thr PDXK protein. n = 3 at each
data point. (F) Erythrocyte PDXK activity in dried blood spots (DBSs) from cases homozygous for the p.Ala228Thr and
p.Arg220Gln versus controls (age = 15–92 years). Patients homozygous for p.Ala228Thr and p.Arg220Gln have lower activity
than all controls. Activity measured as PLP formed after incubation of a 3mm DBS punch with PL. Each sample was analyzed in
duplicate, and the mean is shown. There was no correlation of PDXK activity with age. (G, H) Comparison of plasma PLP
concentrations (retention time = 2.78/2.84 minutes) in control (red) and cases carrying the PDXK mutation (blue) p.Arg220Gln
(G) and p.Ala228Thr (H) show a significant reduction of PLP in the case samples (7.8 and 9nmol/l, respectively) versus control
(control range = 25–75nmol/l).
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Heterozygote activity (n = 1, F-1-III-1) was within normal
range (4.9pmol DBS−1h−1). No correlation of DBS PL
kinase activity with age was identified in controls. When
segregated according to gender, a difference was identified
between control males and females (9 males: mean = 9.2,
range = 5.9–14.7; 12 females: mean = 7.1, range = 2.6–11.7)
that approached significance (p = 0.1099 by untailed t test).
An insertion located in the erythroid-specific promoter
region of PL kinase has been associated with reduced eryth-
rocyte PDXK activity.21 Sequencing this region showed
that the reduced activity of all affected individuals was not
attributable to this insertion (Supplementary Table 4).42
Finally, we measured plasma PLP concentrations in
all affected individuals. Plasma PLP was greatly reduced in
cases carrying p.Arg220Gln and p.Ala228Thr compared
to age-matched controls (see Fig 3G, H).
To quantify the axonal damage, we measured the
NFL protein in plasma from patients carrying PDXK
mutations. NFL, a major axonal cytoskeletal protein, is
released into cerebrospinal fluid and blood during axonal
breakdown,43 providing a dynamic biomarker of axonal
damage in neurodegenerative disorders, including
inherited neuropathies.44 Both p.Arg220Gln and
p.Ala228Thr variants were associated with high NFL
(Case F2-II-1, 49.6pg/ml; Case F1-II-5, 25pg/ml), within
the range of NFL concentrations published for other axo-
nal CMTs.44
Supplementation with PLP Is Associated with
Biochemical Correction and Clinical
Improvement
Based on clear pathogenicity of the PDXK mutations lead-
ing to low PLP, Case F1-II-5 and F1-II-6 were treated
with oral PLP. High doses of pyridoxine are known to be
neurotoxic45; therefore, we used PLP, which is hydrolyzed
to PL, to increase the upstream PL and force the flux with
an enzyme with a high Km based on our results with
recombinant p.Ala228Thr protein kinetics. We initiated
PLP replacement with 50mg/day PLP, a dose that was
commonly used in adults taking PLP as a vitamin
FIGURE 4: Pyridoxal (PL) 50-phosphate (PLP) supplementation in patients with PDXK mutations can rescue the biochemical
phenotype. (A) Concentrations of plasma B6 vitamers in affected homozygous (hom) cases for p.Ala228Thr (F1-II-5), p.Arg220Gln
(F2-II-2), and a heterozygous (het; F1-III-1) PDXK mutation carrier. The levels prior to supplementation were compared to the
published range of B6 vitamers in adult controls (n = 523)
66 not receiving PLP. All units are nmol/l, except for PNP, which is given
in concentration units. nd = not detected; PA = 4-pyridoxic acid; PM = pyridoxamine; PN = pyridoxine; RI = reference interval.
(B) The effect of PLP supplementation on plasma PLP concentrations in a case with PDXK mutations. The red bar represents the
PLP levels in a group of adult controls with no B6 supplementation. There is a significant difference in the plasma PLP
concentration of F1-II-5 before supplementation (blue bar) and on PLP replacement (magenta bar; ***p < 0.05). The difference
between groups was tested with the use of a 1-way analysis of variance test followed by the Tukey–Kramer test. The horizontal
lines on the bars indicate mean value 1 standard deviation. (C) Neurofilament light chain (NFL) concentrations in plasma from
cases with homozygous p.Arg220Gln and p.Ala228Thr PDXK mutations and a heterozygous carrier (F1-III-1). The blue bars show
that NFL levels prior to PLP supplementation are high and consistent with values published in other inherited peripheral
neuropathies (solid line),44 indicating ongoing axonal damage. The orange, gray, and yellow bars show the NFL levels in the cases
from Family 1 at 4, 12, and 24 months on PLP supplementation, respectively. The levels have reduced to that of normal controls
(dashed line) and continued to improve with longitudinal follow-up, suggesting an amelioration of the axonal breakdown.
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supplement with no reported side effects. We aimed to
achieve plasma PLP concentration above the normal range
by PLP replacement, and this was achieved with
50mg/day.
Two weeks after initiating the supplementation,
plasma PLP levels had increased considerably without any
side effects. PLP levels remained stable at 1, 3, 12, 18,
and 24 months on PLP replacement (Fig 4A, B, Table 2),
with improvement in symptoms (Supplementary Table 5).
Clinical improvement was noted after the first 3 months
of PLP replacement in the absence of any additional phys-
iotherapy. Sensory examination and vision remained
unchanged in both cases. Main motor improvements were
in elbow and wrist flexion/extension and hip and knee
flexion/extension, with modest improvement in finger
extension (see Supplementary Table 1), leading to 8- and
6-point improvement in the MRC sum score at 18 months
on PLP replacement in Case F1-II-5 and Case F1-II-6,
respectively. At last examination, 24 months on PLP
replacement, patients were ambulating with high-stepping
gait, unaided (Supplementary Video). Furthermore, neu-
ropathic pain has completely subsided; neither case
requires additional analgesic medication.
These results led to an improvement of 5 points in
the NIS score in Case F1-II-5 and 4 points in Case F1-II-
6 based on motor, pain, and fatigue subsets. Similarly, the
CMT neuropathy score on PLP replacement improved by
4 points and 2 points in Cases F1-II-5 and F1-II-6,
respectively (see Supplementary Table 5).
Electrophysiological studies performed 18 months
after PLP supplementation have demonstrated no disease
progression, with no significant changes in the motor and
sensory responses. Whereas the distal motor responses
were not significantly different from previous studies, the
electromyogram of the proximal muscles showed motor
unit recruitment and interference pattern improvement in
the proximal muscles (quadriceps and tibialis anterior
muscles, biceps and flexor carpi radialis) with activity pre-
sent in the tibialis anterior that was unrecordable on previ-
ous studies.
The clinical response to PLP replacement was fur-
ther supported by measuring NFL protein in plasma
before and after PLP replacement from the PDXK cases in
Family 1. A reduction of NFL levels to the normal control
range44 (median = 13pg/ml, range = 11–18pg/ml; see
Fig 4C) occurred upon restoration of PLP levels and con-
tinued to improve with PLP supplementation. At
24 months with PLP supplementation, the NFL level was
2.5 times lower than before supplementation.
Discussion
Here, we show that biallelic mutations in PDXK lead to
peripheral neuropathy with optic atrophy. We have shown
previously that several inherited disorders affecting B6
vitamer metabolism, or resulting in inactivation of PLP, are
implicated in neurological conditions. These include PNPO
(Mendelian Inheritance in Man [MIM]: 603287),48
ALDH7A1 (MIM: 266100),49,50 and PROSC deficiency
TABLE 2. Plasma B6 Vitamer Profiles for Patients with PROSC, PNPO, and PDXK Deficiency Supplemented with
PLP
Age B6 (dose) PLP PL PA PN PNP PMP PM
Control rangea 4.3–16 years None 46–321 5–18 16–139 nd–0.6 nd nd–9 nd
PROSCb 3 years PLP (70mg QDS) 2,769c 796c 2,043c 0.5 nd nd nd
PROSCb 6 months PLP (45mg/kg/day) 2,166c 1,695c 700c nd nd nd nd
PNPOd 2 years PLP (30mg/kg/d) 580c 427c 793c 575c 43c 18c 193c
PNPOd 10 years PLP (30mg/kg/d) 633c 5,798c 7,926c 599c 77c 101c 2,731c
PDXKe 79 years PLP (50mg/d) 415c 1,550c 1,617c 31c nd nd nd
All units are given as nmol/L, except for PNP, which is given in concentration units.
aControl range as described in Footitt et al46.
bData from Darin et al47.
cValues outside the reference range.
dData from Footitt et al 2013. PLP doses received by PROSC and PNPO patients were larger than the doses given to the pyruvate kinase–deficient
patients (II-5 and II-6).
eValues at 12 months on treatment with PLP.
nd = not detected; PA = 4-pyridoxic acid; PL = pyridoxal; PLP = pyridoxal 50-phosphate; PM = pyridoxamine; PMP = pyridoxamine 50-phosphate;
PN = pyridoxine; PNP = pyridoxine 50-phosphate; QDS = 4 times per day.
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(MIM: 604436),51,52 where the lack of PLP in the brain
leads to early onset, vitamin B6-dependent epilepsy refractory
to anticonvulsants. In most cases, delayed vitamin B6 supple-
mentation results in early death or severe handicap in these
disorders. The PDXK activity is tissue-specific under PLP-
deficiency conditions. In rats, B6 deficiency leads to rapid
decreases in PDXK activity in the peripheries (liver, muscle,
and plasma), with maintained PDXK activity and B6 supply
in the brain.53,54 This could explain the absence of seizures
in humans with PDXK deficiency who present predomi-
nantly with peripheral nerve disease and normal CNS func-
tion. Furthermore, our PDXK co-expression network
analyses from peripheral nerve suggest a link to a module
enriched for genes involved in oxidation-reduction processes
in which mitochondria play a significant role. PLP is a cofac-
tor for several mitochondrial enzymes, but it is not certain
how PLP is transported into mitochondria in humans; in
yeast, there is evidence for involvement of Mtm1p.55
Although we acknowledge that coexpression networks gener-
ated from bulk RNA-seq of peripheral nerves are complex to
interpret, there is growing evidence for the presence and
importance of axonal RNA transport.56–58 Thus, our find-
ings are interesting given the strong phenotypic similarity
(optic atrophy and axonal polyneuropathy) to other disorders
TABLE 3. Vitamin B6–Related Disease Models
Model Phenotype Mechanism Effect on B6 Pathway
Response to PLP
Supplementation
Pharmacological models
Isoniazid, L-dopa,
gentamicin,
D-penicillamine
Axonal peripheral neuropathy1 Interaction between the
reactive aldehyde group of
PLP, with nucleophilic
acceptors such as amine,
hydrazine, hydroxylamine, or
sulfydryl groups rendering
PLP inactive
Decrease in serum PLP Prevents onset of peripheral
neuropathy
Methylxanthines Axonal peripheral
neuropathy2,3
Directly inhibit enzymes
involved in B6 metabolism
Carbamazepine,
vigabatrin, sodium
valproate
Axonal peripheral
neuropathy4–7
Potent hepatic inducers of
cytochrome P450, induce
enzymes involved in the
catabolism of PLP
B6 antivitamin
ginkgotoxin
(40-O-methylpyridoxine)
Epileptic convulsions, leg
paralysis, and loss of
consciousness8
Analogue of PLP; inhibition
of pyridoxal kinase by serving
as an alternate substrate for
the enzyme
Decrease in PLP formation NA
Animal models
Mouse Preweaning lethality, MGI:
1351869
PDXK knockout NA NA
Mouse Abnormal walking track
patterns, axonal peripheral
neuropathy with intact myelin
on nerve biopsy9
PLP dietary-deficient Decrease in serum PLP Complete reversal of
symptoms with PLP
supplementation
Rat Tissue-specific PDXK
response to B6 deficiency
10,11
B6 diet deficient PDXK activity rapidly
decreases in the liver, muscle,
and plasma compared to the
brain
Reversal with PLP
supplementation
Caenorhabditis elegans Sensory–motor integration
deficit in neuromuscular
behavior12
PDXK knockout NA Rescued by expression of a
WT transgene
Drosophila Motility and eye dysfunction
with compromised climbing
ability, ommatidial array
disruption, and decreased
longevity13
PDXK knockdown by RNA
interference
NA Rescued by expression of a
WT transgene
PLP = pyridoxal 50-phosphate; MGI = Mouse Genome Informatics; NA = not applicable; WT = wild-type.
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caused by mutations in genes involved in mitochondrial
functions associated with neurodegeneration, such as OPA1
(MIM: 605290), DHTKD1 (MIM: 614984), MFN1
(MIM: 608506), and MFN2 (MIM: 608507). Interestingly,
within the PDXK regulon from the tibial nerve, we found
DHTKD1 already linked to Mendelian disorders and associ-
ated with primary peripheral axonal neuropathy.59,60 This
suggests that within this regulon there may be other genes
involved in neuronal maintenance that could cause a similar
disease phenotype to be discovered.
Clinically, the PDXK-related neuropathy presented
with mixed sensory and motor involvement in early child-
hood and was associated with optic atrophy later in adult-
hood. Electrophysiologically, one of the earliest signs of the
disease was the absence of sensory responses even when the
motor responses were within normal limits, as seen in Fam-
ily 2. We note that the patients with longstanding disease
(Family 1) had significant standing and walking difficulties
despite a mild proximal motor deficit most likely due to
the combination of severe distal motor involvement with
severe proprioceptive impairment, extending to the proxi-
mal joints, exacerbated by the severely impaired vision.61
Based on our collective experience in rare diseases, we
acknowledge that it is difficult to implement randomized
case–control studies for these patients and the subsequent
limitations when designing therapeutic interventions. We
note that some clinical improvements seen in the patients
reported here, such as pain and fatigue, are susceptible to
placebo effects. Furthermore, the severity of the poly-
neuropathy in the cases that received PLP supplementation
and the absence of more proximal nerve conduction studies
are limitations for the characterization of the neurophysio-
logical phenotype and response to treatment. However,
although we are limited in our ability to fully explain the
mechanism of clinical improvement, the supplementation
with PLP was associated with normalization of the biochem-
ical profile and improved clinical outcomes in individuals
F1-II-5 and F1-II-6. The clinical improvement was
supported by the normalization of PLP levels, stable electro-
physiological picture, and NFL normalization after treat-
ment. Furthermore, animal models of PDXK knockdown,
B6 dietary deficiency, and pharmacological models all
showed significant decreases in circulating PLP levels, with
reversible adverse effect(s) on the peripheral/sensory nerve
similar to the human phenotype observed here (Table 3).
The severe sensory involvement recorded at least 20 years
before treatment most likely accounted for the absence of a
clinical effect on the sensory function in the 2 patients from
Family 1. We are limited in our ability to fully quantify the
potential for electrophysiological improvement at this stage
in the disease due to severe axonal loss, the short interval of
PLP replacement, and the absence of more proximal nerve
conduction studies. Therefore, larger studies with treatment
started earlier in the disease are warranted to assess the full
potential benefit from treatment.
Conclusions
We show that biallelic mutations in PDXK cause autoso-
mal recessive axonal peripheral polyneuropathy leading to
disease via reduced PDXK enzymatic activity and low
PLP. We show that the biochemical profile in affected
individuals can be rescued with PLP supplementation and
that this is associated with improvement in clinical scales.
Therefore, we recommend that PDXK mutations should
be screened for in patients with autosomal recessive early
onset polyneuropathy, and supplementation with PLP
should be started promptly with long-term monitoring of
clinical outcomes. Furthermore, B6 vitamers can be linked
to diseases through a wide range of processes and genes
involved in the vitamin B6 pathway. Therefore, our results
can be extended to other neuropathies of different etiology
characterized by reduction of PLP levels or reduction of
PLP-dependent enzyme activities. Collectively, these data
expand the genetic causes of primary polyneuropathy and
the heterogeneity of inborn errors of vitamin B6 metabo-
lism and identify PLP as a potential therapeutic target for
this disorder.
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